VIVS
NASDAQVivoSim Labs Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News25/Ratings0
News · 26 weeks24+67%
2025-10-262026-04-19
Mix1690d
- Insider5(31%)
- SEC Filings5(31%)
- Other4(25%)
- Leadership1(6%)
- Offering1(6%)
Latest news
25 items- SECVivoSim Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - VivoSim Labs, INC. (0001497253) (Filer)
- SECSEC Form 424B4 filed by VivoSim Labs Inc.424B4 - VivoSim Labs, INC. (0001497253) (Filer)
- PRVivoSim Announces Pricing of up to a $4 Million Public OfferingSAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS), (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the pricing of up to a $4 million best-efforts public offering, with $3 million funded at an initial closing of the offering (the "Initial Closing") and another $1 million to be funded on the 30th day following the date of the Initial Closing, subject to the satisfaction of certain conditions (the "Second Closing"). The Initial Closing of the offering is expected to occur on, April 1, 2026, subject to the satisfaction of customary closing conditions. The Initial Closing of the p
- SECSEC Form EFFECT filed by VivoSim Labs Inc.EFFECT - VivoSim Labs, INC. (0001497253) (Filer)
- SECAmendment: SEC Form S-1/A filed by VivoSim Labs Inc.S-1/A - VivoSim Labs, INC. (0001497253) (Filer)
- SECSEC Form S-1 filed by VivoSim Labs Inc.S-1 - VivoSim Labs, INC. (0001497253) (Filer)
- PRVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsSAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology ("SOT") meeting in San Diego, CA, that its NAMkind™ liver and NAMkind™ Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific solutions to separate anticancer activity f
- PRVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appointment of Dr. Arumugham (Ragoo) Raghunathan, PhD as Vice President of Global Sales. Based in the Greater Boston area, Dr. Raghunathan will lead commercial expansion and secure strategic partnerships with biopharma innovators, established pharmaceutical companies, CROs/CDMOs, and research institutions. His focus will be on delivering VivoSim's liver and gastrointestinal (GI) toxicity solutions for earlier de-risking of drug candidates and clearer feasibility decisions thro
- SECSEC Form 10-Q filed by VivoSim Labs Inc.10-Q - VivoSim Labs, INC. (0001497253) (Filer)
- PRVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoSAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it will attend the Society of Toxicology ("SOT") meeting in San Diego, CA that takes place March 22-25 and present new data on its NAMkind™ liver and NAMkind™ Intestine model, including data on validating the models for use in predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). Considering the hundreds of ADCs in development across the globe, the potential for off target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a
- INSIDERDirector Cohen Douglas Jay was granted 15,000 shares, increasing direct ownership by 262% to 20,732 units (SEC Form 4)4 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDEREXECUTIVE CHAIRMAN Murphy Keith was granted 15,000 shares, increasing direct ownership by 136% to 26,053 units (SEC Form 4)4 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDERDirector Milhous Alison Tjosvold was granted 15,000 shares, increasing direct ownership by 306% to 19,899 units (SEC Form 4)4 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDERDirector Gobel David was granted 15,000 shares (SEC Form 4)4 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDERDirector Stern Adam K was granted 15,000 shares, increasing direct ownership by 306% to 19,899 units (SEC Form 4)4 - VivoSim Labs, INC. (0001497253) (Issuer)
- PRVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim's commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines. A market inflect
- PRVivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific OfficerSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advance
- SECVivoSim Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - VivoSim Labs, INC. (0001497253) (Filer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Sethi Amar Akhtar4 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sethi Amar Akhtar3 - VivoSim Labs, INC. (0001497253) (Issuer)
- INSIDERSEC Form 4 filed by Director Gobel David4 - VivoSim Labs, INC. (0001497253) (Issuer)
- SECSEC Form 10-Q filed by VivoSim Labs Inc.10-Q - VivoSim Labs, INC. (0001497253) (Filer)
- SECSEC Form DEFA14A filed by VivoSim Labs Inc.DEFA14A - VivoSim Labs, INC. (0001497253) (Filer)
- SECSEC Form DEF 14A filed by VivoSim Labs Inc.DEF 14A - VivoSim Labs, INC. (0001497253) (Filer)
- SECSEC Form RW filed by VivoSim Labs Inc.RW - VivoSim Labs, INC. (0001497253) (Filer)